Astria Therapeutics Inc (NAS:ATXS)
$ 9.395 0.385 (4.27%) Market Cap: 515.91 Mil Enterprise Value: 219.53 Mil PE Ratio: 0 PB Ratio: 1.89 GF Score: 36/100

Astria Therapeutics Inc Preliminary Results From The Phase 1a Clinical Trial Of STAR-0215 Transcript

Dec 15, 2022 / 01:30PM GMT
Release Date Price: $11.26 (+2.27%)
Operator

Good day, and welcome to the Astria Therapeutics Phase Ia results conference call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker, Ms. Andrea Matthews, Senior Vice President of Corporate Affairs. Please go ahead.

Andrea L. Matthews
Astria Therapeutics, Inc. - SVP of Corporate Affairs

Thank you. Welcome to today's Astria Therapeutics' STAR-0215 Phase Ia results conference call. With me today are Jill Milne, Chief Executive Officer; Christopher Morabito, Chief Medical Officer; Andy Nichols, Chief Scientific Officer; Andrew Komjathy, Chief Commercial Officer; and Noah Clauser, Chief Financial Officer.

We issued a press release this morning summarizing the results from our Phase Ia trial with the STAR-0215 program, which is available on our website. We are also using slides during today's call that are available within the webcast and on the Events & Presentations section of our website.

I would like to note that during today's event,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot